# US 10,765,727 B2 · Compositions and methods for producing dendritic cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,727 B2
- Document ID: US10765727B2
- Status: Granted
- Kind: B2
- Application number: 15/275,073
- Filed: 2016-09-23
- Published: 2017-03-30
- Granted: 2020-09-08
- Earliest claimed: 2015-09-26
- Assignees: Primevax Immuno-Oncology, Inc.
- Applicants: PrimeVax Immuno-Oncology, Inc.
- Inventors: Bruce W. Lyday; Tony Chen
- Web page: https://patentgrep.com/patent/US10765727B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4245: {Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}
- A61K 40/4271: {Melanoma antigens}
- A61K 40/4273: {Glycoprotein 100 [Gp100]}
- A61P 35/00: Antineoplastic agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55533: {IL-2}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 2501/05: Adjuvants
- C12N 2501/052: Lipopolysaccharides [LPS]
- C12N 2501/24: Interferons [IFN]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2770/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2770/24171: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and/or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

## Claims

### Claim 1

A method for treating or reducing melanoma, comprising:
obtaining primed dendritic cells by a process comprising the steps of: contacting dendritic cells with a tumor antigen, lipopolysaccharide, R848, and interferon-gamma;
administering the primed dendritic cells to a subject in need thereof; and
administering a Dengue Virus to the subject, wherein the Dengue Virus is serotype 2 strain #1710, and wherein the subject has melanoma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the primed dendritic cells are administered intravenously.

### Claim 3 (depends on 1)

The method of claim 1, wherein the tumor antigen is obtained from a cancer cell of the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the primed dendritic cells are autologous or allogenic to the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the primed dendritic cells produce 15 to 19 ng/mL of IL-12p70.

### Claim 6 (depends on 1)

The method of claim 1, wherein the primed dendritic cells produce 15 to 23 ng/mL of IL-12p70.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mouse.

### Claim 9 (depends on 1)

The method of claim 1, wherein the primed dendritic cells are prepared by culturing on a hard surface.

### Claim 10 (depends on 9)

The method of claim 9, wherein the hard surface is substantially free from a fluorinated polyethylene, a fluorinated polypropylene, or a phthalate.

### Claim 11 (depends on 1)

The method of claim 1, wherein the Dengue Virus is isolated from a Vero cell line.